ALEXANDRIA REAL ESTATE EQUITIES, INC. (ARE)
Alexandria Real Estate Equities, Inc. (ARE) is a publicly traded real estate investment trust that specializes in owning and leasing properties to life sciences and biotech companies. The company operates across the United States, focusing on laboratory, office, and related real estate that serves the research, development, and manufacturing sectors of the life sciences industry.
What the company does
Alexandria Real Estate Equities operates as a specialized property owner and lessor within the life sciences sector. The company acquires, develops, and manages a diversified portfolio of laboratory, office, and related properties designed for pharmaceutical, biotechnology, and research-focused tenants. These properties span across key life sciences hubs in the United States, including regions known for concentrations of biotech and pharmaceutical activity. The company’s real estate includes both fully developed facilities and properties held for future development.
How it makes money
As a REIT, Alexandria generates revenue primarily through real estate leases. The company collects rental income from tenants occupying its laboratory and office properties. Tenants typically enter into long-term lease agreements, providing relatively stable cash flows. The company also manages property operations, maintenance, and improvements. Alexandria may earn additional revenue through development of properties and their subsequent lease or sale.
REITs like Alexandria are structured to distribute substantially all taxable income to shareholders in the form of dividends, rather than retain earnings for corporate purposes. This structure defines the REIT business model and shapes how the company returns value to investors.
Where it sits in its industry
Alexandria operates within the broader real estate investment trust sector, competing with other REITs that own various property types—office, industrial, residential, and medical. Its distinctive focus is on life sciences properties, a more specialized segment that serves pharmaceutical, biotechnology, and research institutions. This specialization positions the company in a niche market where demand is driven by the growth and operations of life sciences companies rather than general commercial real estate trends.
The company’s ability to serve the specific operational and technical needs of life sciences tenants—including laboratory infrastructure, regulatory compliance, and build-to-suit development—differentiates it from generalist commercial real estate owners.
How to research it
Alexandria files regular 10-K annual and 10-Q quarterly reports with the SEC, available through the SEC’s EDGAR database. These filings contain detailed information about the company’s property portfolio, tenant composition, lease terms, financial performance, and capital allocation strategy.
Investors can examine the company’s property holdings by geographic region, tenant industry, and lease maturity schedule to understand portfolio concentration and renewal risks. Tenant quality and diversity—whether the portfolio relies on few major tenants or maintains broad tenant bases—are relevant factors for assessing revenue stability.
The 10-K and 10-Q documents describe property development activities, capital expenditures, debt levels, and distribution policies, providing the framework for evaluating how the company reinvests in its portfolio and returns cash to shareholders.